PIRS Palvella Therapeutics Inc.


$ 81.30 $ 3.69 (4.74 %)    

Wednesday, 12-Nov-2025 15:59:59 EST
QQQ $ 620.05 $ -3.74 (-0.6 %)
DIA $ 482.76 $ 2.24 (0.47 %)
SPY $ 682.23 $ -1.55 (-0.23 %)
TLT $ 90.10 $ 0.16 (0.18 %)
GLD $ 385.20 $ 5.86 (1.54 %)
$ 81.54
$ 78.04
$ 70.50 x 1
$ 87.00 x 25
$ 75.73 - $ 83.00
$ 11.17 - $ 83.00
182,431
na
na
$ -0.33
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 palvella-therapeutics-announces-first-patient-dosed-in-selva-phase-3-clinical-trial-of-qtorin-39-rapamycin-anhydrous-gel-for-the-treatment-of-microcystic-lymphatic-malformations

Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treat...

 palvella-therapeutics-and-pieris-pharmaceuticals-to-merge-creating-a-nasdaq-listed-entity-with-805m-cash-to-drive-development-of-novel-skin-disease-therapies

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing...

 pieris-pharmaceuticals-announces-1-for-80-reverse-stock-split

https://www.sec.gov/Archives/edgar/data/1583648/000143774924012442/ex_655549.htm

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION